Amphastar Pharmaceuticals (AMPH) Metrics: History & Chart

Amphastar Pharmaceuticals, Inc.(AMPH)

Drug Manufacturers - Specialty & Generic · Rancho Cucamonga, CA

$25.37-0.06 (-0.24%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.

Rancho Cucamonga, CA

1,976 employees

www.amphastar.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Yongfeng Zhang

View full financials

Third-Party DCF Estimate (FMP)	$82.51
Price Gap vs Third-Party Estimate	+225.21%

7D Total Return	-7.37%
30D Total Return	+9.45%
YTD Total Return	-5.27%
1Y Total Return	-5.16%
3Y Total Return	-45.51%
5Y Total Return	+34.64%
10Y Total Return	+27.63%
15Y Total Return	N/A
20Y Total Return	N/A

2026	-5.27%
2025	-27.88%
2024	-39.97%
2023	+120.74%
2022	+20.31%
2021	+15.81%
2020

CAGR TTM	-5.13%
CAGR 3Y	-18.32%
CAGR 5Y	+6.13%
CAGR 10Y	+2.47%
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	15.01
PE Ratio Avg TTM	11.42
PE Ratio Avg 3Y	12.91
Current VS TTM Avg	+31.49%
Current VS 3Y Avg	+16.24%
Current VS 5Y Avg	-15.67%

All Metrics

AMPH Valuation Metrics

AMPH Stock Price Metrics

AMPH Dividend Metrics

AMPH Growth Rate Metrics

AMPH Discounted Cash Flow Metrics

AMPH Returns By Period

AMPH Yearly Returns

AMPH Average Annual Returns By Period (CAGR)

AMPH Revenue Metrics

AMPH PE Ratio Metrics

AMPH PS Ratio Metrics

AMPH PB Ratio Metrics

AMPH Price to Free Cash Flow Ratio Metrics

AMPH Debt to Equity Ratio Metrics

AMPH PEG Ratio Metrics

AMPH FCF Yield

AMPH Earnings Yield

AMPH EBITDA Yield

AMPH OCF Yield

AMPH EV/EBIT Ratio Metrics

AMPH EV/EBITDA Ratio Metrics

AMPH EV/Assets Ratio Metrics

AMPH EV/Sales Ratio Metrics

AMPH Current Ratio Metrics

AMPH Quick Ratio Metrics

AMPH ROIC Metrics

AMPH Return on Assets Metrics

AMPH Return on Equity Metrics

AMPH Net Profit Margin Metrics

AMPH Gross Profit Margin Metrics

AMPH Tax Rate Metrics

PS Ratio	1.54
PS Ratio Avg TTM	1.49
PS Ratio Avg 3Y	2.58
Current VS TTM Avg	+3.41%
Current VS 3Y Avg	-40.25%
Current VS 5Y Avg	-49.74%

PB Ratio	1.46
PB Ratio Avg TTM	1.39
PB Ratio Avg 3Y	2.53
Current VS TTM Avg	+5.08%
Current VS 3Y Avg	-42.25%
Current VS 5Y Avg	-50.65%

PFCF Ratio	7.34
PFCF Ratio Avg TTM	8.70
PFCF Ratio Avg 3Y	11.60
Current VS TTM Avg	-15.65%
Current VS 3Y Avg	-36.75%
Current VS 5Y Avg	-55.14%

Debt/Equity Ratio	0.90
Debt/Equity Ratio Avg TTM	0.87
Debt/Equity Ratio Avg 3Y	0.88
Current VS TTM Avg	+3.57%
Current VS 3Y Avg	+2.16%
Current VS 5Y Avg	+40.38%

PEG Ratio	0.11
PEG Ratio Avg TTM	0.23
PEG Ratio Avg 3Y	0.28
Current VS TTM Avg	-51.47%
Current VS 3Y Avg	-60.06%
Current VS 5Y Avg	-67.68%

FCF Yield	13.63%
FCF Yield Avg TTM	12.18%
FCF Yield Avg 3Y	9.49%
Current VS TTM Avg	+11.95%
Current VS 3Y Avg	+43.69%
Current VS 5Y Avg	+87.11%

Earnings Yield	6.66%
Earnings Yield Avg TTM	8.79%
Earnings Yield Avg 3Y	8.09%
Current VS TTM Avg	-24.20%
Current VS 3Y Avg	-17.71%
Current VS 5Y Avg	+2.51%

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	13.88
Ev/Ebit Ratio Avg TTM	11.44
Ev/Ebit Ratio Avg 3Y	11.30
Current VS TTM Avg	+21.31%
Current VS 3Y Avg	+22.84%
Current VS 5Y Avg	-12.90%

Ev/Ebitda Ratio	8.84
Ev/Ebitda Ratio Avg TTM	7.81
Ev/Ebitda Ratio Avg 3Y	8.49
Current VS TTM Avg	+13.13%
Current VS 3Y Avg	+4.08%
Current VS 5Y Avg	-26.14%

Ev/Assets Ratio	0.91
Ev/Assets Ratio Avg TTM	0.93
Ev/Assets Ratio Avg 3Y	1.40
Current VS TTM Avg	-2.46%
Current VS 3Y Avg	-35.05%
Current VS 5Y Avg	-47.88%

Ev/Sales Ratio	2.17
Ev/Sales Ratio Avg TTM	2.15
Ev/Sales Ratio Avg 3Y	3.23
Current VS TTM Avg	+1.16%
Current VS 3Y Avg	-32.85%
Current VS 5Y Avg	-36.89%

Current Ratio	2.40
Current Ratio Avg TTM	3.34
Current Ratio Avg 3Y	2.90
Current VS TTM Avg	-28.14%
Current VS 3Y Avg	-17.22%
Current VS 5Y Avg	-22.24%

Quick Ratio	1.71
Quick Ratio Avg TTM	2.37
Quick Ratio Avg 3Y	2.12
Current VS TTM Avg	-27.69%
Current VS 3Y Avg	-19.06%
Current VS 5Y Avg	-23.50%

ROIC	5.93%
ROIC Avg 3Y	10.40%
ROIC Avg 5Y	10.24%
Current VS 3Y Avg	-42.97%
Current VS 5Y Avg	-42.05%
Current VS 10Y Avg	+8.25%

ROA	4.50%
ROA Avg TTM	1.32%
ROA Avg 3Y	1.99%
Current VS TTM Avg	+241.35%
Current VS 3Y Avg	+125.62%
Current VS 5Y Avg	+87.22%

ROE	10.23%
ROE Avg TTM	13.01%
ROE Avg 3Y	18.10%
Current VS TTM Avg	-21.38%
Current VS 3Y Avg	-43.47%
Current VS 5Y Avg	-40.23%

Net Profit Margin	10.76%
Net Profit Margin Avg TTM	12.09%
Net Profit Margin Avg 3Y	18.73%
Current VS TTM Avg	-10.97%
Current VS 3Y Avg	-42.54%
Current VS 5Y Avg	-41.22%

Gross Profit Margin	47.68%
Gross Pft Margin Avg TTM	47.94%
Gross Pft Margin Avg 3Y	50.54%
Current VS TTM Avg	-0.54%
Current VS 3Y Avg	-5.66%
Current VS 5Y Avg	-4.42%

Tax Rate	21.26%
Tax Rate Avg 3Y	18.21%
Tax Rate Avg 5Y	19.43%
Current VS 3Y Avg	+16.75%
Current VS 5Y Avg	+9.44%
Current VS 10Y Avg	-16.64%